Pediatric Perfusion Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Pediatric Perfusion Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Pediatric Perfusion Market:

https://www.thebusinessresearchcompany.com/report/pediatric-perfusion-global-market-report

According to The Business Research Company’s Pediatric Perfusion Global Market Report 2024, The pediatric perfusion market size has grown strongly in recent years. It will grow from $2.52 billion in 2023 to $2.73 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to early pediatric cardiac surgery milestones, pioneering perfusion techniques, evolution of pediatric perfusion equipment, foundational research in pediatric cardiology, emergence of pediatric heart centers.

The pediatric perfusion market size is expected to see strong growth in the next few years. It will grow to $3.69 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to global expansion of pediatric cardiac services, advancements in neuroprotection, investments in pediatric cardiac care, customized perfusion solutions, rise in hybrid operating room usage. Major trends in the forecast period include research in pediatric cardiac care, continuous education and training, focus on neuroprotection, pediatric-specific equipment development, evolving cannulation techniques.

The prevalence of cardiac congenital disorders is expected to propel the growth of the pediatric perfusion market going forward. Cardiac congenital disorders refer to defects that are present at birth and can have an impact on the development and functionality of a baby’s heart that affects how blood travels from the heart to the body’s other organs. Pediatric perfusion is extensively used during cardiac surgeries to repair or correct structural defects in the heart and these surgeries may involve procedures such as ventricular septal defect (VSD) repair, atrial septal defect (ASD) repair, tetralogy of Fallot (TOF) repair, coarctation of the aorta repair, and many others. For Instance, in February 2023, according to World Health Organization, a Switzerland-based specialized agency of the United Nations responsible for international public health, congenital diseases are thought to be the cause of 240 000 newborn deaths globally within 28 days of birth each year. Furthermore, according to the report published by the Center for Diseases Control (CDC), in January 2022, a congenital cardiac abnormality affects approximately 40,000 births in the United States each year, accounting for about 1% of the global population. Therefore, the prevalence of cardiac congenital disorders is driving the growth of pediatric perfusion.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10717&type=smp

The pediatric perfusion market covered in this report is segmented –

1) By Product: Pediatric Cannulae, Pediatric Centrifugal Blood Pumps, Pediatric Arterial Filters, Hem concentrators, HMS Plus Hemostasis Management System, Pediatric Oxygenators

2) By Procedure Type: Pediatric Cardiac Surgeries, Pediatric Organ Transplantation, Pediatric Extracorporeal Life Support (ECLS)

3) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-users

Product innovations are a key trend gaining popularity in the pediatric perfusion market. Major market players are concentrating their efforts on creating newer technologies such as cardiopulmonary bypass (CPB), and cardiovascular perfusion, extracorporeal technological advancements such as miniaturized extracorporeal circulation (MECC) systems, pediatric cardiac surgery, advanced oxygenators, and closed-loop perfusion systems. For Instance, in March 2023, LivaNova, a UK-based manufacturer of medical devices, launched Essenz Heart-Lung Machine, in the US region with a 510(k) clearance from the U.S. Food and Drug Administration. LivaNova’s patient monitor and the Essenz Heart-Lung Machine combine to form a perfusion system used during cardiopulmonary bypass surgeries. During an open-heart operation, a perfusion system serves as the patient’s heart and lungs. Additionally, it is suitable for both adult and pediatric patients and is mast-mounted to reduce distractions and maintain the area clean. The cockpit gives a centralized perspective from which to control the device and monitor all perfusion and patient data and also interfaces with external operating room devices and hospital information systems.

The pediatric perfusion market report table of contents includes: